Table 2.
Heart rate and achievement of study definition of rate control according to rhythm status and treatment group
| Baseline rhythm status | Treatment arm | Baseline | Month 3 |
Δ heart rate at month 3 | P-value, Δ from baseline | |
|---|---|---|---|---|---|---|
| Mean ± SD (n) | Mean ± SD (n) | Rate controlled | ||||
| Atrial fibrillation | Placebo | 80 ± 14 (157) | 81 ± 15 (149) | 74/150 (49%) | 2.2 ± 1.1 | 0.02 |
| Bucindolol | 79 ± 14 (146) | 70 ± 13 (138)** | 92/138 (67%)** | –6.9 ± 1.3** | <0.0001 | |
| Sinus rhythm | Placebo | 83 ± 13 (1086) | 80 ± 13 (1021) | 555/1021 (54%) | –2.0 ± 0.4 | <0.0001 |
| Bucindolol | 83 ± 14 (1090) | 73 ± 12 (1008)** | 756/1008 (75%)** | –9.9 ± 0.4** | <0.0001 | |
Rate-controlled ventricular rate ≤80 b.p.m at month 3, no bradycardia adverse events through month 7.
Treatment group comparisons within rhythm subgroups: *P < 0.05, *P < 0.005.